temozolomide has been researched along with shikonin in 3 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (33.33) | 24.3611 |
2020's | 2 (66.67) | 2.80 |
Authors | Studies |
---|---|
Balça-Silva, J; do Carmo, A; Dubois, LG; Echevarria-Lima, J; Ferrer, VP; Lopes, MC; Matias, D; Moura-Neto, V; Pontes, B; Rosário, L; Sarmento-Ribeiro, AB | 1 |
Buchner, A; Lyu, C; Pohla, H; Schrader, I; Sroka, R; Stadlbauer, B; Stepp, H; Werner, M | 1 |
Maeoka, R; Matsuda, R; Morimoto, T; Nakagawa, I; Nakase, H; Nakazawa, T; Nishimura, F; Ouji, Y; Park, YS; Yamada, S; Yokoyama, S; Yoshikawa, M | 1 |
3 other study(ies) available for temozolomide and shikonin
Article | Year |
---|---|
Dual treatment with shikonin and temozolomide reduces glioblastoma tumor growth, migration and glial-to-mesenchymal transition.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Dacarbazine; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Glioblastoma; Humans; Naphthoquinones; Temozolomide | 2017 |
The role of Shikonin in improving 5-aminolevulinic acid-based photodynamic therapy and chemotherapy on glioblastoma stem cells.
Topics: Aminolevulinic Acid; Brain Neoplasms; Cell Line, Tumor; Glioblastoma; Humans; Naphthoquinones; Neoplasm Recurrence, Local; Photochemotherapy; RNA, Messenger; Temozolomide | 2022 |
Local administration of shikonin improved the overall survival in orthotopic murine glioblastoma models with temozolomide resistance.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor; Glioblastoma; Humans; Mice; Mice, Inbred C57BL; Naphthoquinones; Temozolomide | 2023 |